Latest news with #KytheraLabs
Business Wire
16-06-2025
- Health
- Business Wire
New Real-World Study by Columbia Data Analytics Confirms Semaglutide Significantly Reduces Kidney Disease Risk in Patients with Type 2 Diabetes
NEW YORK & ISTANBUL--(BUSINESS WIRE)--A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of major kidney disease events among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in real-world clinical practice. Creating 896,257 external control arm semaglutide users and a comparator group from the Kythera Labs database (2019–2024), the study provides the largest real-world evaluation of semaglutide's renoprotective effects to date. Share Key findings: 26% Reduction in Major Kidney Events: Compared with standard care, semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events, including kidney failure and substantial loss of kidney function. This effect is consistent with, and slightly exceeds, the 24% risk reduction observed in the landmark FLOW clinical trial. Robust Real-World Evidence: Creating 896,257 external control arm semaglutide users and a comparator group from the Kythera Labs database (2019–2024), the study provides the largest real-world evaluation of semaglutide's renoprotective effects to date. Broad Patient Representation: The real-world cohort included a more diverse, representative patient population than typical clinical trials, enhancing the generalizability of the findings. Consistent Results Across Sensitivity Analyses: The study's conclusions remained robust across multiple sensitivity analyses, further supporting the reliability of the results. The researchers constructed an external control arm using real-world data and applied rigorous statistical methods, including propensity score matching and Cox regression, to ensure comparability with the FLOW trial population. The primary outcome was a composite of kidney failure onset and a sustained 50% reduction in estimated glomerular filtration rate. 'These results provide compelling real-world evidence for the use of semaglutide in reducing the risk of kidney failure and progression in patients with type 2 diabetes and CKD,' said lead author Dr. Onur Baser. 'The findings support broader adoption of semaglutide as a renoprotective therapy and may inform clinical guidelines, payer coverage decisions, and health policy.' Although reliance on diagnosis codes and the inability to confirm medication adherence are limitations typical of observational research, the large sample size, advanced statistical adjustments, and consistency with clinical trial data strengthen the findings' validity. About the Study Authors: Onur Baser, PhD (Bogazici University, City University of New York [CUNY] College of Technology) and Yuanqing Lu, MS (Columbia Data Analytics) Data Source: Kythera Labs, 2019–2024 Presented at: ISPOR 2025, Montréal, Québec, Canada Funding: No external funding Conflicts of Interest: None declared Citation: Baser O, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes. Expert Opinion on Pharmacotherapy.
Business Wire
12-06-2025
- Business
- Business Wire
Atropos Health and Kythera Labs Partner to Expand Access to Real-World Data to Advance Oncology
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in generating real-world evidence (RWE) from high-quality healthcare data today announced a partnership with Kythera Labs, a leading healthcare data and technology company, adding to the growing number of datasets and use cases for the Atropos Evidence™ Network including oncology. This is the first step in a multiyear agreement between the two companies committed to turning data and knowledge of molecular biology in health and disease into meaningful health outcomes. With the Kythera Labs collaboration, the Atropos Evidence Network continues to expand, adding the high-quality datasets needed to generate actionable insights. By utilizing Atropos Health's Real World Data Score® (RWDS) & Real World Fitness Score® (RWFS), users can select the dataset that is the most suitable to answer each question. Kythera Labs' Oncology Event asset is a rich, high-fidelity dataset that provides comprehensive insights into the oncology care continuum, including patient interactions, treatment decisions, and provider engagements. Built from Kythera Labs' Remastered Source Data, the Oncology Event asset utilizes Kythera Labs' dynamic common data model and proprietary methodologies to ensure accuracy and depth. Through Atropos Evidence Network, organizations can quickly access actionable insights that support faster and more confident decisions in oncology research, clinical trials, and patient care. 'Growing the multimodal oncology network increases the opportunity for Atropos Evidence Network members to find more 'fit-for-purpose' data' said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. 'Together with Kythera Labs, we will better enable healthcare organizations to accelerate and improve clinical decision making, clinical research productivity and clinical trial site selection and recruitment with novel evidence-based insights.' The Atropos Evidence Network creates a market for data holders to expand the reach of these de-identified assets to a broader audience. Data contributors receive transparent, analytically driven feedback on usage and their own data quality and strengths. Atropos Health is the connection between real-world evidence (RWE) and actionable clinical analytics. With the addition of Kythera Lab's purpose-built, remastered Real World Data, comprehensive, enriched insights into the full oncology care continuum, including patient interactions, provider engagements, and treatment nuances, will help spur innovation and optimize patient care strategies. "At Kythera Labs, we are committed to closing the gaps between R&D and care delivery, moving insights from the clinical bedside to the research bench,' said Jeff McDonald, CEO and co-founder of Kythera Labs. 'Partnerships like this are integral to making progress within the field of oncology. By collaborating with Atropos Health and providing access to our enriched and analytics-ready data assets, we hope to help Evidence Network users reach answers faster and more cost-efficiently.' The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model, forming secure, cloud-based connections between healthcare data proprietors and clinical insight seekers across the healthcare ecosystem. De-identified data doesn't change hands - institutional members of the network, such as a physician or researcher, can pose clinical questions to a variety of datasets. Within 48 hours, the user receives a novel retrospective observational study in response. About Atropos Health Atropos Health is the developer of GENEVA OS™ , the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth. About Kythera Labs Kythera Labs is a data technology company that unifies data science and data technology to enable higher fidelity in healthcare data for Healthcare and Life Sciences organizations. Our multi-source data captures over 310M de-identified unique individuals and our technology is built for RWD users to integrate, access, analyze and find answers. Learn more at or follow Kythera Labs on LinkedIn.
